Trial Profile
A Double-blinded, Placebo-controlled, Crossover Study to Assess Efficacy of Oral Treprostinil Titrated to Highest Tolerable Dose in 20 Patients With Symptomatic Primary or Secondary Raynaud's Phenomenon Resistant to Vasodilatory Therapy
Status:
Completed
Phase of Trial:
Phase 0
Latest Information Update: 12 Jan 2022
Price :
$35
*
At a glance
- Drugs Treprostinil (Primary)
- Indications Raynaud's disease
- Focus Therapeutic Use
- 05 Jan 2022 Status changed from recruiting to completed.
- 14 Jan 2019 Planned End Date changed from 1 Jul 2018 to 1 Jul 2021.
- 14 Jan 2019 Planned primary completion date changed from 1 Jul 2018 to 1 Jul 2021.